About This Guide
About Managed Care's Guide to ADHD Medication Safety.
Purpose
Managed Care's Guide to ADHD Medication Safety synthesizes FDA pharmacovigilance data, peer-reviewed clinical literature, and national guidelines to support evidence-based managed care decisions.
This guide exists because formulary decisions about ADHD medications are frequently made without the full statistical picture. The FAERS concomitant/suspected distinction — the FDA's own classification — is routinely overlooked in policy discussions.
What's Included
| Resource | Details |
|---|---|
| FDA FAERS Analysis | Q1 2024 — 169,640 reports, 18,048 drugs, 1,341 ADHD reports |
| International Research | 38 peer-reviewed studies across 25 countries (2004–2025) |
| U.S. LDX Clinical Trials | 34 clinical trials, PK studies, and meta-analyses |
| Clinical Guidelines | 33 national guidelines and pharmacovigilance protocols |
| HAP Study Data | FDA Human Abuse Potential results for LDX |
| Step Therapy Evidence | Outcomes and cost impact of utilization management |
Key Definitions
Suspected — The drug is believed to have caused or contributed to the adverse event.
Concomitant — The drug was present at the time of the event but is NOT believed to have caused it.
Concomitant rate — Percentage of reports where a drug is classified as concomitant. Higher = less often identified as the cause of harm.
HAP Study — Human Abuse Potential study. FDA gold standard using experienced stimulant user cohorts.
Disclaimer
This guide is for informational and managed care planning purposes only. Nothing here constitutes medical advice or legal guidance. All clinical decisions should be made in consultation with qualified healthcare providers in compliance with applicable requirements.